FY2030 EPS Forecast for Rein Therapeutics Raised by Analyst

Rein Therapeutics Inc. (NASDAQ:RNTX) – Research analysts at HC Wainwright raised their FY2030 earnings estimates for shares of Rein Therapeutics in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of $0.56 for the year, up from their prior estimate of $0.55. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($0.53) per share.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded Rein Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings upgraded Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 3rd. Finally, Maxim Group started coverage on Rein Therapeutics in a research report on Monday, July 20th. They issued a “buy” rating and a $4.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Rein Therapeutics Price Performance

Shares of RNTX stock opened at $0.77 on Wednesday. Rein Therapeutics has a 1 year low of $0.69 and a 1 year high of $2.18. The stock’s 50 day simple moving average is $0.88 and its two-hundred day simple moving average is $1.13. The company has a market cap of $65.87 million, a PE ratio of -0.45 and a beta of 1.39.

Rein Therapeutics (NASDAQ:RNTX) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.17.

Institutional Trading of Rein Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Sigma Planning Corp grew its stake in shares of Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after buying an additional 101,400 shares during the last quarter. Chicago Partners Investment Group LLC lifted its stake in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after acquiring an additional 10,000 shares during the last quarter. State Street Corp lifted its stake in shares of Rein Therapeutics by 374.3% during the 4th quarter. State Street Corp now owns 75,904 shares of the company’s stock worth $88,000 after acquiring an additional 59,900 shares during the last quarter. Voss Capital LP boosted its holdings in Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after acquiring an additional 1,577,437 shares during the period. Finally, Gagnon Securities LLC boosted its holdings in Rein Therapeutics by 5.0% during the 4th quarter. Gagnon Securities LLC now owns 240,220 shares of the company’s stock valued at $279,000 after acquiring an additional 11,528 shares during the period. Institutional investors own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.